Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)

Phase 2 Completed 50 enrolled Merck Sharp & Dohme LLC Ariad Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

The study evaluates efficacy of Ridaforolimus when administered as maintenance therapy to patients with metastatic bone or soft-tissue sarcoma in Japan.

Timeline

Start: 2009-11
Primary completion: 2011-09
Completion: 2013-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ridaforolimus	Small molecule	40 mg	Oral

Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)

Summary

Timeline

Drugs

Indications